What is the most accurate whole-body imaging modality for assessment of local and distant recurrent disease in colorectal cancer? A meta-analysis: Imaging for recurrent colorectal cancer

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 38, Issue 8, 2011, Pages 1560-1571

  Maas, Monique ^a   Rutten, Iris J G ^a   Nelemans, Patty J ^b   Lambregts, Doenja M J ^a   Cappendijk, Vincent C ^a   Beets, Geerard L ^a   Beets Tan, Regina G H ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Colorectal cancer; Recurrence; Staging; Whole body imaging

Indexed keywords

CARCINOEMBRYONIC ANTIGEN;

ADULT; AGED; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL PRACTICE; COLORECTAL CANCER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTINGENCY TABLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; EMBASE; FEMALE; HUMAN; MALE; MEDLINE; META ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; RECEIVER OPERATING CHARACTERISTIC; RECURRENT DISEASE; REVIEW; RISK; SENSITIVITY AND SPECIFICITY; WHOLE BODY IMAGING;

COLORECTAL NEOPLASMS; HUMANS; NEOPLASM RECURRENCE, LOCAL; ROC CURVE; WHOLE BODY IMAGING;

EID: 80052587317     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-011-1785-1     Document Type: Review

References (73)

1. Cancer Research UK. http://www.cancerresearchuk.org/.
2. Chen LB, Tong JL, Song HZ, Zhu H, Wang YC. (18)F-DG PET/ CT in detection of recurrence and metastasis of colorectal cancer. World J Gastroenterol 2007;13:5025-9. (Pubitemid 47496838)
3. Elias D, Sideris L, Pocard M, Ouellet JF, Boige V, Lasser P, et al. Results of R0 resection for colorectal liver metastases associated with extrahepatic disease. Ann Surg Oncol 2004;11:274-80. (Pubitemid 40486767)
4. Pfannschmidt J, Bischoff M, Muley T, Kunz J, Zamecnik P, Schnabel PA, et al. Diagnosis of pulmonary metastases with helical CT: The effect of imaging techniques. Thorac Cardiovasc Surg 2008;56:471-5.
5. Wiering B, Ruers TJ, Krabbe PF, Dekker HM, Oyen WJ. Comparison of multiphase CT, FDG-PET and intra-operative ultrasound in patients with colorectal liver metastases selected for surgery. Ann Surg Oncol 2007;14:818-26. (Pubitemid 46175332)
6. Imbriaco M, Akhurst T, Hilton S, Yeung HW, Macapinlac HA, Mazumdar M, et al. Whole-body FDG-PET in patients with recurrent colorectal carcinoma. A comparative study with CT. Clin Positron Imaging 2000;3:107-14.
7. Kim JH, Czernin J, Allen-Auerbach MS, Halpern BS, Fueger BJ, Hecht JR, et al. Comparison between 18F-FDG PET, in-line PET/ CT, and software fusion for restaging of recurrent colorectal cancer. J Nucl Med 2005;46:587-95. (Pubitemid 41716402)
8. Willkomm P, Bender H, Bangard M, Decker P, Grünwald F, Biersack HJ. FDG PET and immunoscintigraphy with 99mTclabeled antibody fragments for detection of the recurrence of colorectal carcinoma. J Nucl Med 2000;41:1657-63.
9. Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development of QUADAS: A tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 2003;3:25.
10. Zamora J, Abraira V, Muriel A, Khan K, Coomarasamy A. Meta- DiSc: A software for meta-analysis of test accuracy data. BMC Med Res Methodol 2006;6:31.
11. Moses LE, Shapiro D, Littenberg B. Combining independent studies of a diagnostic test into a summary ROC curve: Dataanalytic approaches and some additional considerations. Stat Med 1993;12:1293-316. (Pubitemid 23230833)
12. Antoch G, Vogt FM, Freudenberg LS, Nazaradeh F, Goehde SC, Barkhausen J, et al. Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. JAMA 2003;290:3199-206. (Pubitemid 38020681)
13. Butch RJ, Stark DD, Wittenberg J, Tepper JE, Saini S, Simeone JF, et al. Staging rectal cancer by MR and CT. AJR Am J Roentgenol 1986;146:1155-60. (Pubitemid 16099539)
14. Furukawa H, Ikuma H, Seki A, Yokoe K, Yuen S, Aramaki T, et al. Positron emission tomography scanning is not superior to whole body multidetector helical computed tomography in the preoperative staging of colorectal cancer. Gut 2006;55:1007-11. (Pubitemid 43962614)
15. Goshen E, Davidson T, Aderka D, Zwas ST. PET/CT detects abdominal wall and port site metastases of colorectal carcinoma. Br J Radiol 2006;79:572-7. (Pubitemid 44083391)
16. Pijl ME, Wasser MN, Joekes EC, van de Velde CJ, Bloem JL. Metastases of colorectal carcinoma: Comparison of soft- and hardcopy helical CT interpretation. Radiology 2003;227:747-51. (Pubitemid 36583031)
17. Selzner M, Hany TF, Wildbrett P, McCormack L, Kadry Z, Clavien PA. Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver? Ann Surg 2004;240:1027-34. discussion 1035-6.
18. Squillaci E, Manenti G, Mancino S, Cicció C, Calabria F, Danieli R, et al. Staging of colon cancer: Whole-body MRI vs. wholebody PET-CT-initial clinical experience. Abdom Imaging 2008;33:676-88.
19. Thomson V, Pialat JB, Gay F, Coulon A, Voloch A, Granier A, et al. Whole-body MRI for metastases screening: A preliminary study using 3D VIBE sequences with automatic subtraction between noncontrast and contrast enhanced images. Am J Clin Oncol 2008;31:285-92.
20. Veit P, Kühle C, Beyer T, Kuehl H, Herborn CU, Börsch G, et al. Whole body positron emission tomography/computed tomography (PET/CT) tumour staging with integrated PET/CT colonography: Technical feasibility and first experiences in patients with colorectal cancer. Gut 2006;55:68-73. (Pubitemid 41820638)
21. Abdel-Nabi H, Doerr RJ, Lamonica DM, Cronin VR, Galantowicz PJ, Carbone GM, et al. Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: Correlation with histopathologic and CT findings. Radiology 1998;206:755-60. (Pubitemid 28128526)
22. Brauck K, Zenge MO, Vogt FM, Quick HH, Stock F, Trarbach T, et al. Feasibility of whole-body MR with T2- and T1-weighted real-time steady-state free precession sequences during continuous table movement to depict metastases. Radiology 2008;246:910-6.
23. Kantorová I, Lipská L, Bělohlávek O, Visokai V, Trubac M, Schneiderová M. Routine (18)F-FDG PET preoperative staging of colorectal cancer: Comparison with conventional staging and its impact on treatment decision making. J Nucl Med 2003;44:1784-8. (Pubitemid 39663310)
24. Komori T, Narabayashi I, Matsumura K, Matsuki M, Akagi H, Ogura Y, et al. 2-[Fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography versus whole-body diffusion-weighted MRI for detection of malignant lesions: Initial experience. Ann Nucl Med 2007;21:209-15. (Pubitemid 47387439)
25. Kong G, Jackson C, Koh DM, Lewington V, Sharma B, Brown G, et al. The use of 18F-FDG PET/CT in colorectal liver metastases- comparison with CT and liver MRI. Eur J Nucl Med Mol Imaging 2008;35:1323-9.
26. LonneuxM,Delval D, Bausart R,Moens R,Willockx R,Van Mael P, et al. Can dual-headed 18F-FDG SPET imaging reliably supersede PET in clinical oncology? A comparative study in lung and gastrointestinal tract cancer. Nucl Med Commun 1998;19:1047-54. (Pubitemid 28551835)
27. Lubezky N, Metser U, Geva R, Nakache R, Shmueli E, Klausner JM, et al. The role and limitations of 18-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) scan and computerized tomography (CT) in restaging patients with hepatic colorectal metastases following neoadjuvant chemotherapy: Comparison with operative and pathological findings. J Gastrointest Surg 2007;11:472-8.
28. Ogunbiyi OA, Flanagan FL, Dehdashti F, Siegel BA, Trask DD, Birnbaum EH, et al. Detection of recurrent and metastatic colorectal cancer: Comparison of positron emission tomography and computed tomography. Ann Surg Oncol 1997;4:613-20. (Pubitemid 127725488)
29. Rosa F, Meimarakis G, Stahl A, Bumm R, Hahn K, Tatsch K, et al. Colorectal cancer patients before resection of hepatic metastases. Impact of (18)F-FDG PET on detecting extrahepatic disease. Nuklearmedizin 2004;43:135-40. (Pubitemid 39121138)
30. Ruers TJ, Langenhoff BS,Neeleman N, Jager GJ, Strijk S,Wobbes T, et al. Value of positron emission tomography with [F-18]fluorodeoxyglucose in patients with colorectal liver metastases: A prospective study. J Clin Oncol 2002;20:388-95. (Pubitemid 34072520)
31. Schlemmer HP, Schäfer J, Pfannenberg C, Radny P, Korchidi S, Müller-Horvat C, et al. Fast whole-body assessment of metastatic disease using a novel magnetic resonance imaging system: Initial experiences. Invest Radiol 2005;40:64-71. (Pubitemid 40144410)
32. Stecco A, Romano G, Negru M, Volpe D, Saponaro A, Costantino S, et al. Whole-body diffusion-weighted magnetic resonance imaging in the staging of oncological patients: Comparison with positron emission tomography computed tomography (PET-CT) in a pilot study. Radiol Med 2009;114:1-17.
33. Topal B, Flamen P, Aerts R, D'Hoore A, Filez L, Van Cutsem E, et al. Clinical value of whole-body emission tomography in potentially curable colorectal liver metastases. Eur J Surg Oncol 2001;27:175-9. (Pubitemid 32621731)
34. Falk PM, Gupta NC, Thorson AG, Frick MP, Boman BM, Christensen MA, et al. Positron emission tomography for preoperative staging of colorectal carcinoma. Dis Colon Rectum 1994;37:153-6. (Pubitemid 24083066)
35. Gearhart SL, Frassica D, Rosen R, Choti M, Schulick R, Wahl R. Improved staging with pretreatment positron emission tomography/ computed tomography in low rectal cancer. Ann Surg Oncol 2006;13:397-404. (Pubitemid 43255924)
36. Khan S, Tan YM, John A, Isaac J, Singhvi S, Guest P, et al. An audit of fusion CT-PET in the management of colorectal liver metastases. Eur J Surg Oncol 2006;32:564-7. (Pubitemid 44226008)
37. Nahas CS, Akhurst T, Yeung H, Leibold T, Riedel E, Markowitz AJ, et al. Positron emission tomography detection of distant metastatic or synchronous disease in patients with locally advanced rectal cancer receiving preoperative chemoradiation. Ann Surg Oncol 2008;15:704-11.
38. Ono K, Ochiai R, Yoshida T, Kitagawa M, Omagari J, Kobayashi H, et al. Comparison of diffusion-weighted MRI and 2-[fluorine- 18]-fluoro-2-deoxy-D- glucose positron emission tomography (FDG-PET) for detecting primary colorectal cancer and regional lymph node metastases. J Magn Reson Imaging 2009;29:336-40.
39. Schiepers C, Penninckx F, De Vadder N, Merckx E, Mortelmans L, Bormans G, et al. Contribution of PET in the diagnosis of recurrent colorectal cancer: Comparison with conventional imaging. Eur J Surg Oncol 1995;21:517-22.
40. Tateishi U, Maeda T, Morimoto T, Miyake M, Arai Y, Kim EE. Non-enhanced CT versus contrast-enhanced CT in integrated PET/CT studies for nodal staging of rectal cancer. Eur J Nucl Med Mol Imaging 2007;34:1627-34. (Pubitemid 47476922)
41. Tsunoda Y, Ito M, Fujii H, Kuwano H, Saito N. Preoperative diagnosis of lymph node metastases of colorectal cancer by FDGPET/ CT. Jpn J Clin Oncol 2008;38:347-53. (Pubitemid 351753566)
42. Veit P, Antoch G, Stergar H, Bockisch A, Forsting M, Kuehl H. Detection of residual tumor after radiofrequency ablation of liver metastasis with dual-modality PET/CT: Initial results. Eur Radiol 2006;16:80-7. (Pubitemid 43103572)
43. Vitola JV, Delbeke D, Sandler MP, Campbell MG, Powers TA,Wright JK, et al. Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver. Am J Surg 1996;171:21-6. (Pubitemid 26028187)
44. Zerhouni EA, Rutter C, Hamilton SR, Balfe DM, Megibow AJ, Francis IR, et al. CT and MR imaging in the staging of colorectal carcinoma: Report of the Radiology Diagnostic Oncology Group II. Radiology 1996;200:443-51. (Pubitemid 26249898)
45. Zhuang H, Sinha P, Pourdehnad M, Duarte PS, Yamamoto AJ, Alavi A. The role of positron emission tomography with fluorine- 18-deoxyglucose in identifying colorectal cancer metastases to liver. Nucl Med Commun 2000;21:793-8.
46. Ntinas A, Zambas N, Al Mogrambi S, Petras P, Chalvatzoulis E, Frangandreas G, et al. Postoperative follow-up of patients with colorectal cancer: A combined evaluation of CT scan, colonoscopy and tumour markers. Tech Coloproctol 2004;8 Suppl 1:s190-2.
47. Saunders TH, Mendes Ribeiro HK, Gleeson FV. New techniques for imaging colorectal cancer: The use of MRI, PET and radioimmunoscintigraphy for primary staging and follow-up. Br Med Bull 2002;64:81-99. (Pubitemid 35238581)
48. Shin SS, Jeong YY, Min JJ, Kim HR, Chung TW, Kang HK. Preoperative staging of colorectal cancer: CT vs. integrated FDG PET/CT. Abdom Imaging 2008;33:270-7. (Pubitemid 351537885)
49. Wong CY, Salem R, Raman S, Gates VL, Dworkin HJ. Evaluating 90Y-glass microsphere treatment response of unresectable colorectal liver metastases by [18F]FDG PET: A comparison with CT or MRI. Eur J Nucl Med Mol Imaging 2002;29:815-20.
50. Yang QM, Bando E, Kawamura T, Tsukiyama G, Nemoto M, Yonemura Y, et al. The diagnostic value of PET-CT for peritoneal dissemination of abdominal malignancies. Gan To Kagaku Ryoho 2006;33:1817-21.
51. Yoshioka T, Fukuda H, Fujiwara T, Iwata R, Ido T, Murakawa Y, et al. FDG PET evaluation of residual masses and regrowth of abdominal lymph node metastases from colon cancer compared with CT during chemotherapy. Clin Nucl Med 1999;24:261-3. (Pubitemid 29156339)
52. Zhang C, Chen Y, Xue H, Zheng P, Tong J, Liu J, et al. Diagnostic value of FDG-PET in recurrent colorectal carcinoma: A metaanalysis. Int J Cancer 2009;124:167-73.
53. Flamen P, Stroobants S, Van Cutsem E, Dupont P, Bormans G, De Vadder N, et al. Additional value of whole-body positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose in recurrent colorectal cancer. J Clin Oncol 1999;17:894-901. (Pubitemid 29109320)
54. Johnson K, Bakhsh A, Young D, Martin Jr. TE, Arnold M. Correlating computed tomography and positron emission tomography scan with operative findings in metastatic colorectal cancer. Dis Colon Rectum 2001;44:354-7. (Pubitemid 32226323)
55. Fong Y, Saldinger PF, Akhurst T, Macapinlac H, Yeung H, Finn RD, et al. Utility of 18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases. Am J Surg 1999;178:282-7.
56. Veit-Haibach P, Kuehle CA, Beyer T, Stergar H, Kuehl H, Schmidt J, et al. Diagnostic accuracy of colorectal cancer staging with whole-body PET/CT colonography. JAMA 2006;296:2590-600. (Pubitemid 44903862)
57. Arulampalam T, Costa D, Visvikis D, Boulos P, Taylor I, Ell P. The impact of FDG-PET on the management algorithm for recurrent colorectal cancer. Eur J Nucl Med 2001;28:1758-65. (Pubitemid 33141239)
58. Cohade C, Osman M, Leal J, Wahl RL. Direct comparison of (18) F-FDG PET and PET/CT in patients with colorectal carcinoma. J Nucl Med 2003;44:1797-803. (Pubitemid 39663312)
59. Delbeke D, Vitola JV, Sandler MP, Arildsen RC, Powers TA, Wright Jr. JK, et al. Staging recurrent metastatic colorectal carcinoma with PET. J Nucl Med 1997;38:1196-201. (Pubitemid 27332611)
60. Lonneux M, Reffad AM, Detry R, Kartheuser A, Gigot JF, Pauwels S. FDG-PET improves the staging and selection of patients with recurrent colorectal cancer. Eur J Nucl Med Mol Imaging 2002;29:915-21. (Pubitemid 34671297)
61. Nakamoto Y, Sakamoto S, Okada T, Senda M, Higashi T, Saga T, et al. Clinical value of manual fusion of PET and CT images in patients with suspected recurrent colorectal cancer. AJR Am J Roentgenol 2007;188:257-67. (Pubitemid 46012519)
62. Ruhlmann J, Schomburg A, Bender H, Oehr P, Robertz-Vaupel GM, Vaupel H, et al. Fluorodeoxyglucose whole-body positron emission tomography in colorectal cancer patients studied in routine daily practice. Dis Colon Rectum 1997;40:1195-204.
63. Schmidt GP, Baur-Melnyk A, Haug A, Utzschneider S, Becker CR, Tiling R, et al. Whole-body MRI at 1.5 T and 3 T compared with FDG-PET-CT for the detection of tumour recurrence in patients with colorectal cancer. Eur Radiol 2009;19:1366-78.
64. Staib L, Schirrmeister H, Reske SN, Beger HG. Is (18)Ffluorodeoxyglucose positron emission tomography in recurrent colorectal cancer a contribution to surgical decision making? Am J Surg 2000;180:1-5.
65. Valk PE, Abella-Columna E, Haseman MK, Pounds TR, Tesar RD, Myers RW, et al. Whole-body PET imaging with [18F] fluorodeoxyglucose in management of recurrent colorectal cancer. Arch Surg 1999;134:503-11. discussion 511-3.
66. Whiteford MH, Whiteford HM, Yee LF, Ogunbiyi OA, Dehdashti F, Siegel BA, et al. Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum. Dis Colon Rectum 2000;43:759-67. discussion 767-70.
67. Kamel IR, Cohade C, Neyman E, Fishman EK, Wahl RL. Incremental value of CT in PET/CT of patients with colorectal carcinoma. Abdom Imaging 2004;29:663-8. (Pubitemid 39331699)
68. Blomqvist L, Holm T, Göranson H, Jacobsson H, Ohlsén H, Larsson SA. MR imaging, CT and CEA scintigraphy in the diagnosis of local recurrence of rectal carcinoma. Acta Radiol 1996;37:779-84. (Pubitemid 126710175)
69. Pema PJ, Bennett WF, Bova JG, Warman P. CT vs MRI in diagnosis of recurrent rectosigmoid carcinoma. J Comput Assist Tomogr 1994;18:256-61. (Pubitemid 24100013)
70. Stückle CA, Haegele KF, Jendreck M, Kickuth R, Schneider O, Hohlbach G, et al. Improvements in detection of rectal cancer recurrence by multiplanar reconstruction. Radiologe 2005;45:930-4, 936.
71. Valentini V, Aristei C, Glimelius B, Minsky BD, Beets-Tan R, Borras JM, et al. Multidisciplinary Rectal Cancer Management: 2nd European Rectal Cancer Consensus Conference (EURECACC2). Radiother Oncol 2009;92:148-63.
72. Titu LV, Breen DJ, Nicholson AA, Hartley J, Monson JR. Is routine magnetic resonance imaging justified for the early detection of resectable liver metastases from colorectal cancer? Dis Colon Rectum 2006;49:810-5. (Pubitemid 43846616)
73. Titu LV, Nicholson AA, Hartley JE, Breen DJ, Monson JR. Routine follow-up by magnetic resonance imaging does not improve detection of resectable local recurrences from colorectal cancer. Ann Surg 2006;243:348-52. (Pubitemid 43327766)